Search


	Podcast:		The Bio Report
	Episode:		A Diagnostics Company Moves to Developing Precision Cancer Therapies
	Category:		Business
	Duration:		00:29:01
	Publish Date:		2021-05-06 08:00:11
	Description:		Earlier this year NovelluxDx rebranded itself as Fore Biotherapeutics signaling a shift from being a diagnostics company to its new life as a precision cancer therapeutics drug developer. Building on its functional genomics platform, the company is in-licensing small molecule drug candidates it sees having potential to treat hyper-targeted patient populations. We spoke to Usama Malik, CEO of Fore Biotherapeutics, about the move from diagnostics to drug development, the approach Fore is taking, and why it thinks it can see value in molecules that others may miss.
	Total Play:		0

Some more Podcasts by Levine Media Group

600+ Episodes

The Bio Repo ..